Anthony Kanelidis, MD
Cardiovascular Disease · Chicago, ILNPI 1881122059
Payments from drug & device makers
What this record shows
This record is dominated by grants: $9,000 of the $13,538 with a category attached, or 66.5%. Abbott accounts for 77.6% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2023 at $10,065 and has fallen 93.3% since, to $676 in 2025.
Across 150 payments — averaging $90.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$11K
- AstraZeneca$528
- Pfizer$492
- Abiomed$374
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$245
- Amgen$229
- plus $1K from 21 others
What the payments were for
- Grants$9,00066%
- Travel & lodging$170%
- Food & beverage$4,07430%
- Education$4463%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 23 | $10,509 |
| AstraZeneca | 28 | $528 |
| Pfizer | 27 | $492 |
| Abiomed | 7 | $374 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $245 |
| Amgen | 8 | $229 |
| Boston Scientific | 5 | $174 |
| Johnson & Johnson | 10 | $139 |
| Paragonix Technologies, Inc. | 2 | $138 |
| Novartis | 4 | $104 |
| Lantheus Medical Imaging, Inc. | 5 | $104 |
| Edwards Lifesciences | 3 | $71 |
| Boehringer Ingelheim | 3 | $59 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Alnylam Pharmaceuticals Inc. | 1 | $44 |
| ZOLL Circulation Inc | 1 | $35 |
| Cardiva Medical, Inc. | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Medtronic | 1 | $28 |
| Sanofi | 1 | $25 |
| United Therapeutics Corporation | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Bayer | 1 | $20 |
| Terumo Medical Corporation | 1 | $18 |
| Merck | 1 | $16 |
| Cvrx, Inc. | 1 | $15 |
| Livanova USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$748
- ENSITE$205
- ENSITE PRECISION$151
- Impella$148
- HeartMate 3 Left Ventricular Dev$138
- ELIQUIS$123
- Repatha$122
How this compares
$13,538 in reported general payments places this provider in the 85th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Furosemide | 22 | $99 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Chicago
- Sandeep NathanChicago$892K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Michael DavidsonChicago$317K
- Jyothy PuthumanaChicago$269K
- Sanjiv ShahChicago$246K
- Raja MutharasanChicago$146K
- Nitasha SarswatChicago$140K
- Evan SteinChicago$121K
- Dan FintelChicago$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.